Impact and Outcomes of Pretreatment Total Serum Testosterone on Localized Prostate Cancer Patients
Table. 1
Clinical demographic features of the study population.
All patients
Unweighted baseline cohort
Propensity-weighted cohort
Testosterone cohort
Absolute standardized difference
value
Absolute standardized difference
value
Cohort
1
2
3
1vs2
1vs3
2vs3
1vs2
1vs3
2vs3
1vs2
1vs3
2vs3
1vs2
1vs3
2vs3
Total
100–239
240–593
594+
# of patients
258
39
176
43
Age (yrs)
63.9
65.4
64.5
0.20
0.08
0.12
0.21
0.69
0.48
0.11
0.03
0.08
0.56
0.89
0.64
%
%
%
%
ADT used with therapy
ADT used
19
10.3
18.8
27.9
0.21
0.44
0.23
0.21
0.05
0.19
0.16
0.16
0.00
0.47
0.07
0.98
No ADT
81
89.7
81.3
72.1
0.21
0.44
0.23
0.16
0.16
0.00
NCCN-risk group
High/VH risk
20.9
23.1
21
18.6
0.05
0.11
0.06
0.29
0.89
0.27
0.10
0.00
0.10
0.85
0.97
0.72
Intermediate risk
50.4
41
54
44.2
0.26
0.06
0.20
0.01
0.05
0.06
Low risk
28.7
35.9
25
37.2
0.24
0.03
0.27
0.09
0.06
0.15
Therapy
Brachytherapy
57.8
59
56.8
60.5
0.04
0.03
0.07
0.62
0.14
0.40
0.15
0.1
0.05
0.60
0.70
0.95
EBRT
16.3
23.1
17
7
0.17
0.45
0.28
0.02
0.12
0.11
EBRT + LDR
14
7.7
14.2
18.6
0.18
0.31
0.12
0.03
0.04
0.01
Surgery
12
10.3
11.9
14
0.05
0.11
0.06
0.21
0.24
0.03
ISUP grade group
Group 1,2
76.9
68.8
65.1
0.18
0.25
0.08
0.19
0.26
0.82
Group 3
5.1
16.5
16.3
0.31
0.30
0.01
Group 4,5
17.9
14.8
18.6
0.09
0.02
0.11
Clinical T-stage
T1c
20.9
51.3
63.6
55.8
0.26
0.09
0.16
0.25
0.92
0.45
T2
50.4
41
33
37.2
0.17
0.08
0.09
T3a/b
28.7
7.7
3.4
7
0.22
0.04
0.18
Body mass index
25–29.9
18.6
20.5
17.6
20.9
0.08
0.01
0.09
0.9119
0.53
0.338
30+
15.9
15.4
18.2
7
0.08
0.23
0.31
<25
7.4
7.7
6.8
9.3
0.03
0.06
0.10
Unknown
58.1
56.4
57.4
62.8
0.02
0.04
0.05
Smoking history
Current
7
7.7
5.1
14
0.10
0.25
0.35
0.54
0.57
0.24
Former
24.8
33.3
23.9
20.9
0.22
0.29
0.07
Never
50.4
43.6
52.3
48.8
0.17
0.11
0.07
Unknown
17.8
15.4
18.8
16.3
0.09
0.02
0.06
Pre-treatment PSA
10–20
32.2
41
31.3
27.9
0.21
0.29
0.07
0.43
0.46
0.79
<10
59.7
53.8
59.7
65.1
0.12
0.23
0.11
>20
8.1
5.1
9.1
7
0.14
0.07
0.08
values for the demographics are calculated based on the chi-squared test. Clinical T-stage derived from the American Joint Committee on Cancer (AJCC) 8th edition. Comparison of standardized difference for the unweighted and propensity weight populations used in the analyses are shown. EBRT = external beam radiation therapy, VH=very high, GS = Gleason score, ADT = Androgen deprivation therapy, ISUP = International Society of Urological Pathologists.